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The aim of this study was to investigate the efficacy and safety of chemoradiation using capecitabine and irinotecan as neoadjuvant
therapy for patients with rectal cancer. Conventional radiation was given at daily fractions of 1.8Gy on 5 days a week for a total dose
of 55.8 (50.4þ5.4)Gy. Concurrently, irinotecan 40mgm
 2 once weekly and capecitabine continuously at dose levels of 500, 650,
750 and 825mgm
 2 twice daily were administered. Surgery was performed 4–6 weeks following completion of chemoradiation. A
total of 28 patients (3 UICC II, 25 UICC III) were enrolled and all received treatment. Dose-limiting toxicity was diarrhoea grade IV
and hand–foot syndrome at the 825mgm
 2 dose level. The maximum tolerated dose of capecitabine was 750mgm
 2. Diarrhoea
was the most common toxicity: grade III in nine patients. Two patients died, one due to pneumonia and one due to sudden cardiac
death. A complete response and only microfocal residual tumour disease was achieved in four and three patients (27%). In all, 25 of
28 patients undergoing surgery, 24 (96%) had R0 resection. Preoperative chemoradiation based on continuous daily capecitabine and
weekly irinotecan appears to tolerated and effective in patients with rectal cancer.
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Achieving tumour resection with clear margins (R0) is the most
important prognostic factor in rectal carcinoma and the principal
objective of treatment (Hermanek and Wittekind, 1994) while
maintaining faecal continence is an important objective for
maintaining patients’ quality of life. In locally advanced rectal
cancer (LARC), it can be difficult or impossible to achieve both of
these objectives and local recurrence and metastases can be a
major problem following curative surgery (Hurby et al, 2003).
Radiotherapy or chemoradiation has been widely used to improve
patient outcomes in locally advanced rectal cancer (LARC), 5-FU-
based chemoradiation is an effective treatment, shown by many
phase II studies (Chen et al, 1994; Kaminsky-Forrett et al, 1998;
Janjan et al, 1999; Crane et al, 2003). Preoperative chemoradiation
increases the resection rate (Reerink et al, 2003) and preoperative
radiation or chemoradiotherapy decrease local recurrence and
reduce small bowel complications compared with postoperative
therapy (Minsky et al, 1992; Frykholm et al, 1993, Sauer et al,
2004). R0 resection rates of 60–85% have reported with 5-FU-
based preoperative chemoradiation for LARC (Videtic et al, 1998;
Ku ¨chenmeister et al, 2000; Ro ¨del et al, 2000).
Continuous infused application of 5-FU significantly improves
overall and disease-free survival compared with bolus administra-
tion of 5-FU (O’Connell et al, 1994). However, infused application
is inconvenient and is associated with an increased risk of adverse
venous events, such as infection or thrombosis, and most cancer
patients prefer oral chemotherapy (Liu et al, 1997). Capecitabine,
an oral, tumour-activated fluoropyrimidine carbamate, delivers
5-FU preferentially to tumour cells via enzymatic conversion. The
final step of this process is mediated by the enzyme thymidine
phosphorylase (TP), which is significantly upregulated in tumour
tissue compared with healthy tissue (Schu ¨ller et al, 2000). TP
expression is also enhanced by radiotherapy and the in vivo
antitumour activity of radiotherapy and capecitabine is more than
additive compared with either agent alone (Sawada et al, 1999).
Twice-daily oral administration of capecitabine enables chronic
dosing that results in continuous exposure to 5-FU without
requiring central venous access. As first-line therapy for MCRC,
capecitabine results in superior response rates, improved safety,
and improved convenience compared with 5-FU/LV (Mayo Clinic
regimen) (Van Cutsem et al, 2004). Capecitabine was also
continuously applicated, concurrent to radiotherapy preopera-
tively with good results (Dunst et al, 2002).
The topoisomerase I inhibitor irinotecan has shown consistent
efficacy in both chemotherapy-naive patients and 5-FU-pretreated
patients with metastatic colorectal cancer (Douillard et al, 2000;
Saltz et al, 2000). Also radiosensitizing properties even under
hypoxic conditions were documented (Boothmann et al, 1987;
Boscia et al, 1993), and Irinotecan has also shown in combination
with 5-FU and radiation preoperatively in patients with LARC
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sconsistent efficacy in local control and DFS (Mehta et al, 2003;
Klautke et al, 2005). As a result of that, it was a logical step
to investigate the combination of capecitabine and irinotecan in
patients with LARC.
The aim of this study was to define the maximum tolerated dose
(MTD), dose-limiting toxicity (DLT) and safety profile of
capecitabine in combination with irinotecan and radiotherapy as
preoperative chemoradiation in patients with LARC.
PATIENTS AND METHODS
This was an open-label, 6-week study of increasing dose levels of
capecitabine given concurrently with irinotecan and standard
whole pelvic irradiation as preoperative therapy for rectal cancer
clinical UICC stage II or III.
Patient eligibility
Male and female patients aged 18–75 years were prospectively
enrolled in the study if they presented with histologically
confirmed nonmetastatic adenocarcinoma of the rectum at an
UICC stage II or III. Other inclusion criteria were measurable
disease (at least one bidimensionally measurable tumour lesion),
WHO performance status p2, adequate haematological, hepatic
and renal function, and a life expectancy of at least 3 months.
Pregnant or lactating women, patients with unresolved bowel
obstruction or ileus/subileus and those with a history of chronic
diarrhoea were excluded.
All patients underwent baseline examination and staging
according to the recommendations of the German Cancer Society
within 2–4 weeks prior to the start of chemoradiation, including
history and physical examination, complete blood count, serum
chemistry profile, chest X-ray, rectoscopy or sigmoidoscopy,
endoluminal ultrasound, abdominal ultrasound and computed
tomography (CT) of the abdomen and pelvis. Inclusion of a
minimum of 10 patients in the phase II part and a minimum of 15
patients at the recommended dose level was planned.
The study was approved by the local ethics committee, and
written informed consent was obtained from all patients.
Treatment
CT-assisted 3-dimensional planning of radiation therapy was
employed. The patients underwent CT with 5mm slices, contrast
administration to bladder, rectum and small intestine, and
endoscopic clipping (Riepl et al, 2000) of the upper and lower
border of the tumour performed immediately prior to planning.
Radiation therapy was given with photons from a linear accelerator
with energy 46MV. The target volume comprised the areas at risk
including the presacral space along the posterior bladder or
vaginal wall, respectively, and the common iliac lymph nodes until
and including the fifth lumbar vertebral body. Radiotherapy was
delivered with three or four fields using an isocentric technique
with individually collimated field portals. Daily fractions of 1.8Gy
(calculated at the ICRU 50 reference point) were given on 5 days a
week over 5 weeks to a total dose of 50.4Gy. An additional low-
volume boost of 5.4Gy was given in three fractions to the site of
the primary tumour after previous contrast radiography of the
small intestine.
Radiotherapy was administered with concurrent chemotherapy
consisting of weekly doses of irinotecan 40mgm
 2, given over
90min on days 1, 8, 15, 22, 29 and 36. Patients also received
capecitabine twice daily at 12-h intervals at the following dose
levels: 500, 650 and 825mgm
 2. As the increase from the 650 to
the 825mgm
 2 twice daily capecitabine dose level proved to be too
large during the course of the study, in an amendment a further
dose level of 750mgm
 2 twice daily was introduced before the
dose was increased to 825mgm
 2. So all steps of increasing the
dose from 500mgm
 2 to 825mgm
 2 twice daily capecitabine were
performed adequately.
At the first dose level three patients were planned. If no DLT
occurred, again three patients were planned at the next dose level.
If any DLT occurred, another three patients were treated at the
same dose level. If there was again a DLT, the level below was
the recommended dose level. If there was no DLT another three
patients at the next dose level were planned.
Patients were monitored by history, clinical examination and
blood examination on every Monday and Thursday during the
treatment period.
The chemotherapy was interrupted if any DLT occurred and was
continued at 75% of the original dose when toxicity resolved to
grade I or II. In a case of diarrhoea grade IV radiation and
chemotherapy were interrupted and were continued when diarrhea
resolved to grade II with radiation and 50% of the original dose of
chemotherapy.
Restaging and surgery using total mesorectal excision was to be
performed within 4–6 weeks after completion of chemoradio-
therapy. Following surgery, a postoperative adjuvant chemotherapy
according to the recommendations of the German Cancer Society
was recommended to all patients.
Dose-limiting toxicity
Toxicity was graded according to the National Cancer Institute
Common Criteria (NCI-CTC, version 3.0). Defined DLTs included:
grade IV diarrhoea despite appropriate treatment with antidiar-
rhoea drugs; grade IV haematological side effects; grade IV
mucositis; any other acute side effect at grade IV; severe nausea;
vomiting 6–10 times a day despite the use of antiemetics.
Data evaluation
The deadline for data evaluation was June 30, 2005. Statistical
analysis including survival analysis according to Kaplan–Meier
was performed with the SPSS software package. Survival was
calculated from the date of histologic verification of diagnosis to
the patient’s death or the date of last follow-up. Progression-free
survival was calculated from diagnosis to the time of first detection
of new lesions or progression of residual lesions.
RESULTS
Patient characteristics
Between July 2002 and May 2004, we recruited 28 patients (16
women and 12 men) aged from 48 to 75 years (median, 64 years)
who met all the inclusion criteria. Baseline patient and tumour
characteristics are shown in Table 1. There were two cases of a
primary tumour stage uT2, all lymph node positive, 18 cases of
uT3, all beside two lymph node positive and eight cases at stage
uT4, seven endosonography assessed the lymph node status as
positive. The median length of the tumour, as an approximate
measure of the tumour mass, was 7cm (range 3–15cm). In all, 14
tumours started in the lower third of the rectum, 12 in the middle
and two in the upper third.
Safety
Dose-limiting toxicities did not occur at each of the three patients
at the 500, 650 and 750mgm
 2 twice daily dose levels but were
observed at the 825mgm
 2 twice daily dose. The first three
patients experienced one grade IV diarrhoea with the 825mgm
 2
twice daily dose. The next three patients at this dose level also
reported one grade IV diarrhoea and 1 dose-limiting hand–foot
syndrome. So three further patients were treated at the 750mgm
 2
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stwice daily dose level and no DLT occurred. Therefore, the
recommended dose level was 750mgm
 2 bid capecitabine,
concurrently during radiation and weekly irinotecan (40mgm
 2,
six times). Another 10 patients were included in the phase II part
at this dose level (see Table 2).
The most common toxicity was diarrhoea: grade IV in two
patients at a dose level of 825mgm
 2 and grade III in nine patients
(32%). In addition, four patients (14%) had fever (raised
temperature of over 38.51C), which could be easily controlled with
usual antibiotics. One patient in the phase I part died of
pneumonia, contracted in the intensive care unit, 2 months after
treatment was discontinued early as a result of dose-limiting grade
IV diarrhoea. During the phase II part of the study, one patient
died as a result of a 5-FU-related sudden cardiac death on day 5 of
treatment. There were no grade IV haematological toxicities and
the only grade III haematological toxicity was a single case of
leucopenia (see Table 2). Other toxicity like oral mucositis, hepatic
or renal dysfunction was not observed.
After surgery there was only one anastomotic leakage, treated
by reoperation, and one bowel atony after extirpation, treated
conservatively reported.
Resection
Of the 28 patients enrolled, 25 underwent surgery, two patients
died and one patient did not have surgery because of systemic
progress (peritoneal carcinosis; dose level 500mgm
 2 twice daily).
Of these 25 patients, an R0 resection was possible in 24 cases
(96%); one patient underwent a R1 resection during the first dose
level of 500mgm
 2 (he received additional low-volume radio-
therapy in combination with capecitabine and irinotecan and, as of
June 2005, he is free of distant metastases and local recurrences).
Of the 14 patients with tumours in the lower third (0–5cm), seven
patients had sphincter involvement, so five (36%) underwent
sphincter-sparing surgery, the remaining nine patients underwent
abdominoperineal resection. Of the patients with tumours in the
middle third of the rectum (5.1–10cm), one required abdomino-
perineal resection, while the others were able to undergo
sphincter-sparing surgery (Table 3).
Response
Downstaging for the T category was analysed in 25 patients, who
underwent surgery (Table 4), and response was analysed in the 26
patients who were alive (including one patient who did not
undergo surgery due to systemic progress). Overall, four patients
(15%) had pathological complete response (pCR), and further
Table 1 Baseline patient characteristics
Patients (N¼28)
Variable No. %
Gender
Male 12 43
Female 16 57
Age (years)
Range 48–75
Median 64
T stage
uT2 (uNo/uN+) 2 (0/2) 7
uT3 (uNo/uN+) 18 (2/16) 64
uT4 (uN0/uN+) 8 (1/16) 29
N stage
uN0 3 11
uN+ 25 89
Tumour localization (cm from anal verge)
0–5 14 50
5.5–10 12 43
410 2 7
Tumour length (cm)
Range 3–15
Median 7
Initial Hb value
o13.5gdl
 1 13 46
X13.5gdl
 1 15 54
Table 2 Inicdence and maximum toxicity grade (CTC) according to capecitabine dose levels
Phase I
Phase II
Capecitabine dose 500mgm
 2 bid 650mgm
 2 bid 750mgm
 2 bid 825mgm
 2 bid 750mgm
 2 bid
Toxicity grade (CTC) 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
Number of patients 3 3 3+3 3+3 10
Hematologic
Anemia 3 0 0 0 3 0 0 0 5 1 0 0 6 0 0 0 8 2 0 0
Leucopenia 3 0 0 0 3 0 0 0 4 2 0 0 3 2 1 0 4 6 0 0
Thrombopenia 3 0 0 0 3 0 0 0 6 0 0 0 4 2 0 0 9 1 0 0
Laberatory
Hyperbilirubinaemia 3 0 0 0 3 0 0 0 6 0 0 0 6 0 0 0 10 0 0 0
ALAT/ASAT 3 0 0 0 3 0 0 0 6 0 0 0 6 0 0 0 10 0 0 0
Gastrointestinal
Nausea/vomiting 3 0 0 0 3 0 0 0 4 2 0 0 5 1 0 0 8 2 0 0
Diarrhoea 0 3 0 0 0 3 0 0 0 2 4 0 0 1 3 2 0 8 2 0
Other
Hand–foot syndrome 3 0 0 0 3 0 0 0 6 0 0 0 5 0 1 0 10 0 0 0
Infection 3 0 0 0 2 1 0 0 5 1 0 0 5 1 0 0 9 1 0 0
One patient died of pneumonia in the intensive care unit, after a complete resolved diarrhoea grade IV in the phase I, 2 months after treatment had interrupted; one patient died
as a result of a 5-FU related sudden cardiac death on day 5 of treatment in the phase II.
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sthree cases (12%) had only minimal microfocal residual disease
(MRD). Pathological partial response (pPR) was achieved in
additional 16 patients (62%). In one patient, disease progression
was systemic (peritoneal carcinosis) rather than local at the
500mgm
 2 twice daily dose level. pCRs were observed at the
750mgm
 2 twice daily dose level (three cases) and 825mgm
 2
twice daily level (one case); the MRD cases arose at 650, 750 and
825mgm
 2 (one case at each dose level; Table 5). It is noteworthy
that all the pCR and MRD cases occurred in patients with an initial
haemoglobin value above the median value of 13.5gdl
 1. The
length of the tumour did not affect the pCR and MRD, nor did
the uT or uN stage.
Disease control and survival
All the patients who underwent surgery are alive after a median
observation period of 24 months. One R0 resection patient with his
tumour in the lower third had a local recurrence after 7 months,
one patient had metastases in the liver, which had not been seen
during imaging and were diagnosed during surgery. Another
patient developed liver metastases after 18 months. One patient
developed metastases in the lung after 6 months, another after 15
months. As a result of the short follow-up period the rating of
statistical analysis for survival must be with care. The DFS (30
months) for all patients who underwent surgery is 78% (78%), the
local control 96% (74%), the OS 100%.
DISCUSSION
Preoperative chemoradiation has the potential to increase resect-
ability and improve local control in patients with LARC. In
addition, it can enable patients to undergo more conservative
sphincter-sparing surgery and there is a lower rate of acute side
effects (Sauer et al, 2004). Up to now, it is not known if
preoperative chemoradiation had to be intensified with capecita-
bine, irinotecan or oxaliplatin for better survival data. So the
remission rates are used to compare the different studies of
preoperative-intensified chemoradiotherapy, and also knowing,
that a complete remission to radiation or chemoradiation is
associated with favourable survival (Janjan et al, 2001).
The rate of complete remission is about 10% by using 5-FU or
capecitabine concurrent to radiotherapy (Dunst et al, 2002; Sauer
et al, 2004), by adding irinotecan or oxaliplatin the rate of
complete remission in phase II studies can be more than doubled
(overview by Klautke et al, 2005).
Other studies investigate the combination of preoperative
capecitabine and irinotecan concurrent to radiotherapy (Table 6),
too. The average dose of irinotecan during the period of radio-
therapy was in most studies about 240–250mgm
 2. Looking at
the capecitabine dose and application time, there were more
differences between these studies. So Hofheinz et al (2005)
applicates 500mgm
 2 bid of capecitabine (day 1–38; total dose
of capecitabine: 38000mgm
 2) and reported a high rate of pCR (4/
19; 21%) and MRD (5/19; 26%), and a R0 resection rate of 100%.
Gollins (Gollins et al, 2005) applicates 825mgm
 2 bid from day 1
to 33 continuously (total dose of capecitabine: 54450mgm
 2)
together with four times irinotecan (60mgm
 2). After surgery
there was a R0 resection in 94% and a pCR in 20% (4/20). At this
dose level there was no DLT. In our study, we saw DLT at a dose of
six times irinotecan (40mgm
 2) and capecitabine 825mgm
 2 bid
from day 1–43 (total dose of capecitabine in the dose level with
DLT: 70950mgm
 2; total dose of capecitabine in the recom-
mended dose level: 64500mgm
 2) and we saw the DLT mostly in
the fifth week. The rate of pCR (15%) and R0 – resection seems to
be comparable with these other studies.
In nearly all these studies diarrhoea was the DLT. The
haematological toxicity is not common, in these regimes, and also
oral mucositis was not reported. The hand–foot syndrome was
also no common toxicity at the different recommended doses of
capecitabine. Comparing these results with the results of the
combination 5-FU as continuous infusion and irinotecan weekly
concurrently to radiotherapy (Mitchell et al, 2001; Mehta et al,
2003; Klautke et al, 2005) there were no real differences in efficacy
and toxicity. So the rate of pCR was about 24–37%, and diarrhoea
was the most common toxicity with grade III about 30%. Mitchell
reported also intravenous catheter infections and thrombi as DLT.
And these catheter complications are the big disadvantage of
continuous infused 5-FU and the big advantage of capecitabine.
Table 3 Surgical approach by tumour height
Surgical approach (no. patients)
Tumour
heigt (cm) Sphincter – saving
Abdominop.
Resection Total
0–5 5 9 14
5.5–10 11 1 12
410 2 0 2
Table 4 Pathologic downstaging of the primary tumor
Pathological T stage at
time of surgery (patients)
Clinical T stage at baseline pT0 pT1 pT2 pT3 pT4 Total
c T 2 01100 2
c T 3 406601 6
c T 4 20230 7
Total 619902 5
Table 5 Pathohistological response of 25 patients underwent surgery depending on the dose level of capecitabine
Phase I
Phase II
Capecitabine dose (bid)
Pathohistological response 500mgm
 2 650mgm
 2 750mgm
 2 825mgm
 2 750mgm
 2
N C 20000
p P R 02536
M R D 01011
p C R 00112
Total 23659
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sIt is a great discussion whether oxaliplatin or irinotecan is the best
partner in the preoperative chemoradiotherapy together with capeci-
tabine and radiation and unfortunately there is no effort for a
randomized trial to clear this discussion. The rate of complete response
does not differ using oxaliplatin or irinotecan, but critics mark the high
rate of diarrhoea as disadvantage to irinotecan. Analysing at the study
from Duck et al (2004) using 825mgm
 2 capecitabine bid on each day
of radiation, and weekly 50mgm
 2 oxaliplatin concurrent to radiation,
the most frequent grade III/IV toxicity was diarrhoea in 22%. The pCR
was 6% (1/17). Using continuous infused 5-FU over the whole time of
radiation together with oxaliplatin concurrent to radiotherapy,
diarrhoea also is a DLT (Loi et al, 2005), or was reported in 16% by
a pCR of 28% (7/25) (Aschele et al, 2005).
The preoperative chemoradiotherapy with capecitabine
750mgm
 2 bid, concurrently during radiation (days 1–43)
and weekly irinotecan 40mgm
 2 (six times) seems to be safe
and effective. We need a longer follow-up to verify a potential
benefit for survival in comparing with historical collectives of
patients.
ACKNOWLEDGEMENTS
This work was supported in part by a grant from Aventis Pharma
GmbH, Bad Soden am Taunus, Germany and Hoffmann-La Roche
AG, Grenzach – Wyhlen, Germany.
REFERENCES
Aschele C, Friso ML, Pucciarelli S, Lonardi S, Sartor L, Fabris G, Urso ED,
Del Bianco P, Sotti G, Lise M, Monfardini S (2005) A phase I-II study of
weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative
radiotherapy in locally advanced rectal cancer. Ann Oncol 16: 1140–1146
Becerra CR, Cho L, Gregoreyk S, Simmang C, Frenkel EP, Verma UN (2005)
A Phase I study with irinotecan, capecitabine and radiation therapy for
patients with locally advanced or metastatic rectal cancer. Proc Am Soc
Clin Oncol (Abstr 212)
Boothmann DA, Trask DK, Pardee AB (1987) Inhibition of potential lethal
damage repair in human tumor cells by lapachone, an activator of
topoisomerase I. Cancer Res 49: 605–612
Boscia RE, Korbut T, Holden SA, Ara G, Teicher BA (1993) Interaction of
topoisomerase I inhibitors with radiation in cis-diamminedichloro-
platinum (II)-sensitive and - resistant cells in vitro and in the FSAIIC
fibrosarcoma in vivo. Int J Cancer 53: 118–123
Chen ET, Mohiuddin M, Brodovsky H, Fishbein G, Marks G (1994) Down-
staging of advanced rectal cancer following combined preoperative chemo-
therapy and high dose radiation. Int J Radiat Oncol Biol Phys 30: 169–175
Crane CH, Skibber JM, Feig BW, Vauthey JN, Thames HD, Curley SA,
Rodriguez-Bigas MA, Wolff RA, Ellis LM, Delclos ME, Lin EH, Janjan NA
(2003) Response to preoperative chemoradiation increases the use of
sphincter-preserving surgery in patients with locally advanced low rectal
carcinoma. Cancer 97: 517–524
Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P,
Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P
(2000) Irinotecan combined with fluorouracil compared with fluoro-
uracil alone as first-line treatment for metastatic colorectal cancer: a
multicentre randomised trial. Lancet 355: 1041–1047
Duck LR, Sempoux C, Honhon B, Coster B, Coche J-C, Kerger J, Canon J-L,
Humblet Y, Scalliet P, Machiels J-P (2004) A phase II study of
preoperative oxaliplatin, capecitabine, and external beam radiotherapy
in patients with locally advanced rectal adenocarcinoma. Proc Am Soc
Clin Oncol (Abstr 3552)
Dunst J, Reese T, Sutter T, Zuhlke H, Hinke A, Kolling-Schlebusch K,
Frings S (2002) Phase I trial evaluating the concurrent combination
of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 20:
1005–1009
Frykholm GJ, Glimelius B, Pahlman L (1993) Preoperative or postoperative
irradiation in adenocarcinoma of the rectum: Final treatment results of a
randomized trial and an evaluation of late secondary effects. Dis Colon
Rectum 36: 564–572
Gollins SW, Myint S, Levine E, Morris J, Haylock B, Susnerwala S, Saunders
M, Biswas A (2005) Phase I study of radiotherapy (RT) plus concurrent
irinotecan (CPT-11) and capecitabine (CAP) as preoperative down-
staging treatment for locally advanced inoperable rectal cancer. Proc Am
Soc Clin Oncol (Abstr 3565)
Table 6 Overview of phase I or phase I/II studies with preoperative chemoradiotherapy using capecitabine and irinotecan concurrent to radiation
Study
No of
patients
Capecitabine
(mgm
 2 bid)
Irinotecan
(mgm
 2/week)
Radiotherapy
(Gy) pCR (%) pCR+MRD R0 DLT
Hofheinz et al
(2005)
19 500/625 50 45+5,4 21 4+5/19 19/19 Diarrhoea
Day 1–38 5 
Gollins et al (2005) 20 650/825 50/60/70 45 20 4+4/20 16/17 Diarrhoea
Day 1–33 4  Neutrope nic
fever
Becerra et al
(2005)
12 850 30/40/50 45+5,4 Study is ongoing
Day 1–5;5,5
weeks
5 
Kennedy et al
(2004)
12 500/650/800 40 45+5,4 8 1+2/12 12/12 Study is ongoing
Day 1–5;5,5
weeks
4 
Present study 28 500/650/750/
800
40 50,4+5,4 15 4+3/26 24/25 Diarrhoea
Day 1–43 6  Hand–feet
syndrome
The underlined dose is the recommended dose level.
Concurrent chemoradiation with capecitabine
G Klautke et al
980
British Journal of Cancer (2006) 94(7), 976–981 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sHermanek P, Wittekind C (1994) The pathologist and the residual tumor
(R) classification. Pathol Res Pract 190: 115–123
Hofheinz R, von Gerstenberg-Helldorf B, Wenz F, Gnad U, Kraus-
Tiefenbacher U, Muldner A, Hehlmann R, Post S, Hochhaus A, Willeke
F (2005) Phase I trial of capecitabine and weekly irinotecan in
combination with radiotherapy for neoadjuvant therapy of rectal cancer.
J Clin Oncol 23: 1350–1357
Hurby G, Barton M, Miles S, Carroll S, Nasser E, Stevens G (2003) Site of
local recurrence after surgery, with or without chemotherapy, for rectal
cancer: Implication for radiotherapy field design. Int J Radiat Oncol Biol
Phys 55: 138–143
Janjan NA, Crane C, Feig BW, Cleary K, Dubrow R, Curley S, Vauthey JN,
Lynch P, Ellis LM, Wolff R, Lenzi R, Abbruzzese J, Pazdur R, Hoff PM,
Allen P, Brown T, Skibber J (2001) Improved overall survival among
responders to preoperative chemoradiation for locally advanced rectal
cancer. Am J Clin Oncol 24: 107–112
Janjan NA, Khoo VS, Abbruzzese J, Pazdur R, Dubrow R, Cleary KR, Allen
PK, Lynch PM, Glober G, Wolff R, Rich TA, Skibber J (1999) Tumor
downstaging and sphincter preservation with preoperative chemoradia-
tion in locally advanced rectal cancer: The M.D. Anderson Cancer Center
experience. Int J Radiat Oncol Biol Phys 44: 1027–1038
Kaminsky-Forrett MC, Conroy T, Luporsi E, Peiffert D, Lapeyre M, Boissel
P, Guillemin F, Bey P (1998) Prognostic implications of downstaging
following preoperative radiation therapy for operable T3–T4 rectal
cancer. Int J Radiat Oncol Biol Phys 42: 935–941
Kennedy AS, Kwok Y, Batko-Yovino S, Van Echo DA (2004) A phase I
study of preoperative capecitabine, irinotecan concurrent with radiation
therapy for resectable rectal cancer. Proc Am Soc Clin Oncol (Abstr 268)
Klautke G, Feyerherd P, Ludwig K, Prall F, Foitzik T, Fietkau R (2005)
Intensified concurrent chemoradiotherapy with 5-fluorouracil and
irinotecan as neoadjuvant treatment in patients with locally advanced
rectal cancer. Br J Cancer 92: 1190–1197
Ku ¨chenmeister U, Kirchner R, Mellert J, Klautke G, Mucke R, Hopt UT,
Fietkau R (2000) Erste Ergebnisse der neoadjuvanten simultanen
Radiochemotherapie bei fortgeschrittenen Rektumkarzinomen. Strah-
lenther Onkol 176: 560–566
Liu G, Franssen E, Fitch M, Warner E (1997) Patient preferences for oral
versus intravenous palliative chemotherapy. J Clin Oncol 15: 110–115
Loi S, Ngan SY, Hicks RJ, Mukesh B, Mitchell P, Michael M, Zalcberg
J, Leong T, Lim-Joon D, Mackay J, Rischin D (2005) Oxaliplatin
combined with infusional 5-fluorouracil and concomitant radiotherapy
in inoperable and metastatic rectal cancer: a phase I trial. Br J Cancer 92:
655–661
Mehta VK, Cho C, Ford JM, Jambalos C, Poen J, Koong A, Lin A, Bastidas
JA, Young H, Dunphy EP, Fisher G (2003) Phase II trial of preoperative
3D conformal radiotherapy, protracted venous infusion 5-fluorouracil,
and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal
cancer. Int J Radiat Oncol Biol Phys 55: 132–137
Minsky BD, Cohen AM, Kemeny N, Enker WE, Kelsen DP, Reichman B,
Saltz L, Sigurdson ER, Frankel J (1992) Combined modality therapy of
rectal cancer: decreased acute toxicity with the preoperative approach.
J Clin Oncol 10: 1218–1224
Mitchell EP, Anne P, Fry R, Ahmad N, Boman B, Edmunston T, Rakinic J,
Goldstein S, Rose L, Palazzo J, Cagir B, Kovatich A, Hauck W, Fishel R,
Bonanni R, Hoey D, Rose D, Curran W (2001) Combined mortality
therapy of locally advanced or recurrent adenocarcinoma of the rectum:
report of a phase I trail of chemotherapy with CPT-11, 5-FU and
concomitant irradiation. Proc Am Soc Clin Oncol (Abstr 519)
O’Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller
DG, Mayer RJ, Gunderson LL, Rich TA (1994) Improving adjuvant
therapy for rectal cancer by combining protracted-infusion fluorouracil
with radiation therapy after curative surgery. N Engl J Med 331: 502–507
Reerink O, Verschueren RCJ, Szabo BG, Hospers GA, Mulder NH (2003) A
favourable pathological stage after neoadjuvant radiochemotherapy in
patients with initially irresectable rectal cancer correlates with a
favourable prognosis. Eur J Cancer 39: 192–195
Riepl M, Pietsch A, Klautke G, Fehr R, Fietkau R (2000) Endoscopic
pretherapeutic clipping for gastrointestinal tumors. A method for exact
definition of the target volume. Strahlenther Onkol 176: 517–523
Ro ¨del C, Grabenbauer GG, Schick C, Papadopoulos T, Hohenberger W,
Sauer R (2000) Pra ¨operative simultane Radiochemotherapie mit 5-
Fluorouracil bei lokal fortgeschrittenen T4-Rektumprima ¨rtumoren.
Strahlenther Onkol 176: 161–167
Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun
JA, Ackerland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal
cancer. Irinotecan Study Group. N Engl J Med 343: 905–914
Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R,
Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T,
Schmidtberger H, Raab R, German Rectal Cancer Study Group (2004)
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
N Engl J Med 351: 1731–1740
Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H (1999) X-ray
irradiation induces thymidine phosphorylase and enhances the efficacy
of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 10:
2948–2953
Schu ¨ller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M,
Mori K, Weidekamm E, Reigner B (2000) Preferential activation of
capecitabine in tumor following oral administration to colorectal cancer
patients. Cancer Chemother Pharmacol 45: 291–297
Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour
P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, Mitchell
EP, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A,
Schilsky RL (2004) Oral capecitabine vs intravenous 5-fluorouracil and
leucovorin: integrated efficacy data and novel analyses from two large,
randomized, phase III trials. Br J Cancer 90: 1190–1197
Videtic G, Fisher B, Perera FE, Bauman GS, Kocha WI, Taylor M, Vincent
MD, Plewes EA, Engel CJ, Stitt LW (1998) Preoperative radiation with
concurrent 5-fluorouracil continuous infusion for locally advanced
unresectable rectal cancer. Int J Rad Oncol Biol Phys 42: 319–324
Concurrent chemoradiation with capecitabine
G Klautke et al
981
British Journal of Cancer (2006) 94(7), 976–981 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s